Ten years since the introduction of vedolizumab into clinical practice in inflammatory bowel diseases
Milan Lukáš1
+ Affiliation
To read this article in full, please register for free on this website.
Benefits for subscribers
Benefits for logged users
Literature
1. Hesterberg PE, Winsor-Hines D,Briskin MJ et al. Rapid resolution of chronic colitis in the Cotton-top Tamarin with an antibody to a gut-homing integrin alpha 4 beta 7. Gastroenterology 1996; 111(5): 1373–1380. doi: 10.1053/gast.1996.v111.pm8898653.
2. Feagan BG, Rutgerts P, Sands BE et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013; 369(8): 699–710. doi: 10.1056/NEJMoa1215734.
3. Sandborn WJ, Feagan BJ, Rutgeerts P et al. Vedolizumab as induction and maintenance therapy for Crohn’ s disease. N Engl J Med 2013; 369(8): 711–721. doi: 10.1056/NEJMoa1215739.
4. Bressler B, Yarur A, Silverberg MS at al. Vedolizumab and anti-tumor necrosis factor alpha real world outcomes in biologic naive inflammatory bowel disease patients: results from the EVOLVE study. J Crohn’s Colitis 2021; 15(10): 1694–1706. doi: 10.1093/ecco-jcc/jjab058.
5. Jairath V, Feagan BG, Silverberg MS et al. Mucosal healing with vedolizumab in patients with chronic pouchitis: EARNEST – a randomized, double blind, placebo-controlled study. Clin Gastroenterol Hepatol 2024: S1542-3565(24)00636-0. doi: 10.1016/j.cgh.2024.06.037.
6. Mitrova K, Pipek B, Bortlík M et al. Safety of ustekinumab and vedolizumab during pregnancy-pregnancy, neonatal and infant outcome: a prospective multicentre study. J Crohn’s Colitis J 2022; 16(12): 1808–1815. doi: 10.1093/ecco-jcc/jjac086.